Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Invex Therapeutics Ltd. ( (AU:IXC) ) has shared an announcement.
Invex Therapeutics has reported promising results from its collaboration with Tessara Therapeutics on the effects of Exenatide in treating neurodegenerative conditions such as Alzheimer’s Disease (AD). The research demonstrated that Exenatide enhances neuronal cell survival in a 3D human brain model of AD, showcasing its potential in the $17 billion AD treatment market. Moving forward, Invex plans to explore further collaborations and potential partnerships to expand its pipeline and market opportunities. Financially, the company has maintained a stable cash position, with minimal operating cash outflows and ongoing research and development investments.
More about Invex Therapeutics Ltd.
Invex Therapeutics Ltd is a biopharmaceutical company focused on developing and commercializing Exenatide for neurological conditions associated with raised intracranial pressure.
YTD Price Performance: 9.09%
Average Trading Volume: 16,245
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$5.41M
For an in-depth examination of IXC stock, go to TipRanks’ Stock Analysis page.
